Hospital-acquired infection rapid test

bacteriaMethicillin-resistant Staphylococcus aureusMRSA

The Vivalytic test MRSA/SA provides a quick diagnosis of methicillin resistance at the point of care As a real-time PCR rapid test at the point of care (POC), the Vivalytic test MRSA/SA can detect two of the most important pathogens associated with hospital-acquired infections. Differentiation as to whether the bacterial strain is methicillin-resistant or methicillin-sensitive promotes targeted therapy. The result is available in under one hour, which makes the test a useful addition for determining cultures, especially in emergency situations. Unnecessary, costly isolation measures that are stressful for patients can be avoided. Waiblingen – The new Vivalytic test MRSA/SA for Bosch’s Vivalytic platform is now available. Bosch Healthcare Solutions has once again expanded the test portfolio of this universal PCR system. The Bosch test, developed in cooperation with partner r-biopharm, detects methicillin-resistant staphylococcus aureus (MRSA), one of the most important pathogens for hospital-acquired infections and therefore for associated complications and mortalities. In under an hour, the Vivalytic test MRSA/SA delivers a reliable result1 directly at the point of care and is therefore particularly suitable for use in accident and emergency units. Since the result of diagnostics with cultures is only available after one to three days, this PCR test for the point of care is ideal as an additional tool when speed is of the essence. The quick and reliable diagnosis of whether the bacteria strain is methicillin-sensitive (MSSA) or -resistant is also important in emergency situations. Waiting times for operations can, on the one hand,